Literature DB >> 17324127

Liver biopsy in cirrhotic patients.

Kenneth E Sherman1, Zachary D Goodman, Sara T Sullivan, Sima Faris-Young.   

Abstract

Liver biopsy remains an important tool for the evaluation of patients with hepatic disease. However, clinicians utilize a variety of biopsy techniques including automated cutting needle devices, manual cutting needles, and aspiration needles. Using a large study cohort of patients with advanced fibrosis/cirrhosis we sought to evaluate practices and outcomes of the biopsy technique used by study investigators across the United States. All biopsy samples were from patients with suspected advanced fibrosis or cirrhosis because of hepatitis C virus (HCV) infection. Individual study investigators were permitted to use any biopsy technique. Biopsy specimens were centrally evaluated for tissue adequacy and fragmentation, and were histologically scored using accepted criteria. We evaluated a total of 923 liver biopsy specimens from 502 patients performed at 62 clinical sites. The average duration of HCV infection was 27.9 +/- 0.46 yr. Automated cutting needles were significantly more likely to provide adequate specimens for evaluation than aspiration needles (P < 0.005). Automated cutting needles produced significantly longer biopsies than other techniques (P < 0.05), except for a limited number of cases in which a surgical wedge biopsy was obtained. Tissue fragmentation was observed in 39.2% of liver biopsies obtained using an aspiration technique, but in only 4.7% of samples collected using an automated cutting needle (P < 0.001). We conclude that automated cutting needles provide superior liver biopsy specimens compared with aspiration techniques in subjects with advanced fibrosis/cirrhosis. No specific safety issues attributable to a particular biopsy method were identified.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324127     DOI: 10.1111/j.1572-0241.2007.01110.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

1.  Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.

Authors:  Leonard B Seeff; Gregory T Everson; Timothy R Morgan; Teresa M Curto; William M Lee; Marc G Ghany; Mitchell L Shiffman; Robert J Fontana; Adrian M Di Bisceglie; Herbert L Bonkovsky; Jules L Dienstag
Journal:  Clin Gastroenterol Hepatol       Date:  2010-04-01       Impact factor: 11.382

2.  Targeted and non-targeted liver biopsies carry the same risk of complication.

Authors:  Anna Maheux; Yvonne Purcell; Sana Harguem; Valérie Vilgrain; Maxime Ronot
Journal:  Eur Radiol       Date:  2019-05-10       Impact factor: 5.315

Review 3.  Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.

Authors:  Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2012-07-26       Impact factor: 9.079

4.  Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers.

Authors:  Sami A Gabr; Ahmad H Alghadir
Journal:  Virusdisease       Date:  2013-11-30

5.  Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.

Authors:  Zachary D Goodman; Anne M Stoddard; Herbert L Bonkovsky; Robert J Fontana; Marc G Ghany; Timothy R Morgan; Elizabeth C Wright; Elizabeth M Brunt; David E Kleiner; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; Jules L Dienstag; Chihiro Morishima
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

6.  Ultrasonography in differentiation between chronic viral hepatitis and compensated early stage cirrhosis.

Authors:  Panagiotis Iliopoulos; Marianna Vlychou; Chrisoula Karatza; Spyros-D Yarmenitis; Maria Repanti; Ioannis Tsamis; Kostantinos Tepetes
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

7.  Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

Authors:  Raj Vuppalanchi; Aynur Unalp; Mark L Van Natta; Oscar W Cummings; Kumar E Sandrasegaran; Tariq Hameed; James Tonascia; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-25       Impact factor: 11.382

8.  Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  James E Everhart; Elizabeth C Wright; Zachary D Goodman; Jules L Dienstag; John C Hoefs; David E Kleiner; Marc G Ghany; A Scott Mills; S Russell Nash; Sugantha Govindarajan; Thomas E Rogers; Joel K Greenson; Elizabeth M Brunt; Herbert L Bonkovsky; Chihiro Morishima; Heather J Litman
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

9.  Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures.

Authors:  Aleksandra Szymczak; Krzysztof Simon; Malgorzata Inglot; Andrzej Gladysz
Journal:  Hepat Mon       Date:  2012-01-20       Impact factor: 0.660

10.  Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years.

Authors:  Michael Mueller; Wolfgang Kratzer; Suemeyra Oeztuerk; Manfred Wilhelm; Richard Andrew Mason; Ren Mao; Mark Martin Haenle
Journal:  BMC Gastroenterol       Date:  2012-12-05       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.